Acumen Pharma FY2023 net loss $52.4M; cash $306.1M; Phase 2 AD trial to start H1 2024

Acumen Pharmaceuticals, Inc.

Net loss $52.4M in FY2023 vs $42.9M in 2022; operating loss $61.1M.
Cash, equivalents and marketable securities $306.1M, sufficient for operations into H1 2027.
R&D expenses $42.3M (up $9.9M); G&A $18.8M (up $5.9M).
Plan to initiate Phase 2 ALTITUDE-AD trial of sabirnetug in early AD patients in H1 2024, plus subcutaneous PK study mid-2024.
Appointed Dr. James Doherty as President and Chief Development Officer in Feb 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $52.4 million.

Period: the year ended December 31, 2023
Net income: $52.4 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $52.4 million

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-24-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.